Overactive EGFR Signaling in Pachyonychia Congenita and Treatment With Oral Erlotinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Investigative Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
EGFR signaling is overactive in Pachyonychia congenita: effective treatment with oral erlotinib
J Invest Dermatol 2022 Sep 15;[EPub Ahead of Print], J Basset, L Marchal, A HovnanianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.